by barry101 | Mar 9, 2023 | Press Releases
Annamycin appears to be a highly promising non-cardiotoxic, potent TOPO-II inhibitor able to overcome MDR-1 that, due to its unique organotropism, is also able to target hard-to-treat metastasis In an independent expert cardiology review of 42 subjects evaluated as of...
by barry101 | Mar 1, 2023 | Press Releases
HOUSTON, March 1, 2023 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the first subject has...
by barry101 | Feb 13, 2023 | Press Releases
– Results align with the overall safety profile of Annamycin – Final cohort demonstrated an 80% overall response rate (ORR) in elderly subjects ( 60 years old) – No cardiotoxicity demonstrated in any study subject – The median number of prior...
by barry101 | Jan 5, 2023 | Press Releases
Live video webcast on Tuesday, January 17th at 9:00 AM ET HOUSTON, Jan. 5, 2023 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates...
by barry101 | Dec 21, 2022 | Press Releases
– Ongoing efforts to open additional clinical sites in Poland and to gain approval to proceed in other European countries – First subject treated in Italy expected in the first quarter of 2023 HOUSTON, Dec. 21, 2022 — Moleculin Biotech, Inc.,...
by barry101 | Dec 15, 2022 | Press Releases
Preliminary efficacy updated to 80% overall response rate (ORR) demonstrated in single agent AML trial following database lock Next generation anthracycline, Annamycin, has demonstrated both safety and promising early activity across multiple clinical studies with...
